Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
UBP sees September Fed hold as US inflation cools further

UBP sees September Fed hold as US inflation cools further

ReutersReuters2026/08/17 15:15
  • Union Bancaire Privee flagged softer July US inflation as reinforcing a September Fed hold as the base case.
  • Headline CPI slowed to 3.4% from 3.5%; core CPI eased to 2.5% from 2.6%, while core services re-accelerated.
  • Markets priced down September hike odds to 27% from 70%; 2-year yields fell to 4.17%, 10-year yields rose to 4.69%.
  • Global equities gained 0.7% on the week; energy led as Brent rose to USD 88.55, while gold climbed above USD 4,400.
  • UBP kept a constructive equity view, citing Q2 EPS growth of 32% for the S&P 500, while urging diversification amid geopolitical risks.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Union Bancaire Privee UBP SA published the original content used to generate this news brief on August 17, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

On Monday, storage chip concept stocks generally rose, with SanDisk (SNDK.US) up by 6%.

智通财经2026/08/17 13:51
U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds

On August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 study of Enhertu (trastuzumab deruxtecan) as a monotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has achieved highly positive results.

智通财经2026/08/17 12:56
AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds